NCT00563225View on ClinicalTrials.gov

20 Week Bridging Study in Type II DM

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 31, 2002

Study Completion Date

April 30, 2004

Conditions
Diabetes Mellitus Type II
Interventions
DRUG

Insulin Glargine

Insulin glargine at the discretion of the investigator Subcutaneous, once daily injection (at bedtime)

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00563225 - 20 Week Bridging Study in Type II DM | Biotech Hunter | Biotech Hunter